Staff Publications: April 2017

  1. Aggarwal C, Borghaei H. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. The Oncologist. 2017. PMID: 28408617.
  2. Allen RA, Jennings MC, Mitchell MA, Al-Khalifa SE, Wuest WM, Minbiole KPC. Ester- and Amide-Containing Multiqacs: Exploring Multicationic Soft Antimicrobial Agents. Bioorganic & Medicinal Chemistry Letters. 2017;27(10):2107-2112. PMID: 28392192.
  3. Bauman JE, Cohen E, Ferris RL, et al. Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017;123(7):1259-1271. PMID: 27906454.
  4. Beck TN, Young NG, Erickson ML, Prats I. Rare Antibody-Associated Hemolytic Transfusion Reaction and Transfusion-Related Acute Lung Injury: A Case Report. BMC Surgery. 2017;17(1):48. PMID: 28441942. PMC5405478.
  5. Benson AB, III, Venook AP, Cederquist L, et al. Colon Cancer, Version 1.2017: Clinical Practice Guidelines in Oncology. JNCCN. 2017;15(3):370-398. PMID:28275037.
  6. Boushra M, Tous S, Fetih G, et al. Development and Evaluation of Viscosity-Enhanced Nanocarrier (Ven) for Oral Insulin Delivery. International Journal of Pharmaceutics. 2016;511(1):462-472. PMID: 27418563.
  7. Brzozowski RS, Wuest WM. Twelve-Membered Macrolactones: Privileged Scaffolds for the Development of New Therapeutics. Chemical Biology & Drug Design. 2017;89(2):169-191. PMID: 27153932.
  8. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and Prognosis of Patients with Brain Metastases at Diagnosis of Systemic Malignancy: A Population-Based Study. Neuro-oncology. 2017. PMID: 28444227.
  9. Carraro M, Minervini G, Giollo M, et al. Performance of in Silico Tools for the Evaluation of P16ink4a (Cdkn2a) Variants in Cagi. Human Mutation. 2017. PMID: 28440912.
  10. Chang HW, Studitsky VM. Chromatin Replication: Transmitting the Histone Code. Journal of nature and science. 2017;3(2). PMID: 28393112. PMC5384335.
    Chatare VK, Andrade RB. Total Synthesis of (-)-Albocycline. Angewandte Chemie (International ed in English). 2017. PMID: 28429505.
  11. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and Paclitaxel-Carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-Sensitive Ovarian Cancer (Nrg Oncology/Gynecologic Oncology Group Study Gog-0213): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology. 2017. PMID: 28438473.
  12. Darlow S, Heckman C. Results from a Tailored Sms and Behavior-Tracking Pilot Study on Sun-Safe Behaviors in Young Women. Health Education & Behavior. 2017:1090198117699507. PMID: 28363246.
  13. Deneka AY, Haber L, Kopp MC, Gaponova AV, Nikonova AS, Golemis EA. Tumor-Targeted Sn38 Inhibits Growth of Early Stage Non-Small Cell Lung Cancer (Nsclc) in a Kras/P53 Transgenic Mouse Model. PLoS One. 2017;12(4):e0176747. PMID: 28453558.
  14. Dias MF, Blumenstein R, Russo J. Use of Laser Capture Microdissection Allows Detection of Loss of Heterozygosity in Chromosome 9p in Breast Cancer. Oncology Letters. 2017;13(5):3831-3836.
  15. Escudier B, Motzer RJ, Sharma P, et al. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in Checkmate 025. European Urology. 2017. PMID: 28410865.
  16. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017: Clinical Practice Guidelines in Oncology. JNCCN. 2017;15(4):504-535. PMID: 28404761
  17. Flynn WF, Haldane A, Torbett BE, Levy RM. Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in Hiv-1 Protease. Molecular Biology and Evolution. 2017. PMID: 28369521.
  18. Gerson JN, Skariah S, Denlinger CS, Astsaturov I. Perspectives of Her2-Targeting in Gastric and Esophageal Cancer. Expert Opinion on Investigational Drugs. 2017;26(5):531-540. PMID: 28387541.
  19. Golan S, Johnson SC, Maurice MJ, et al. Safety and Early Effectiveness of Robot-Assisted Partial Nephrectomy for Large Angiomyolipomas. BJU International. 2017;119(5):755-760. PMID: 27988984
  20. Gordon RE, Zhang L, Yang ZJ. Restore the Brake on Tumor Progression. Biochemical Pharmacology. 2017. PMID: 28389227.
  21. Gore JL, Plessis MD, Santiago-Jimenez M, et al. Decipher Test Impacts Decision Making among Patients Considering Adjuvant and Salvage Treatment after Radical Prostatectomy: Interim Results from the Multicenter Prospective Pro-Impact Study. Cancer. 2017. PMID: 28422278.
  22. Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN Guidelines® Insights Breast Cancer, Version 1.2017: Featured Updates to the NCCN Guidelines. JNCCN. 2017;15(4):433-451. PMID: 28404755
  23. Haifler M, Kutikov A. Current Role of Renal Biopsy in Urologic Practice. The Urologic Clinics of North America. 2017;44(2):203-211. PMID: 28411912.
  24. Haldane A, Flynn WF, He P, Vijayan RS, Levy RM. Structural Propensities of Kinase Family Proteins from a Potts Model of Residue Co-Variation. Protein Science. 2016;25(8):1378-1384. PMID: 27241634. PMC4972195.
  25. Heckman CJ, Handorf EA, Darlow SD, Ritterband LM, Manne SL. An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychology. 2017;36(3):215-225. PMID: 27819460. PMCID: PMC5328853
  26. Infante JR, Cohen RB, Kim KB, et al. A Phase I Dose-Escalation Study of Selumetinib in Combination with Erlotinib or Temsirolimus in Patients with Advanced Solid Tumors. Investigational New Drugs. 2017. PMID: 28424891.
  27. Jiang W, Dulaimi E, Devarajan K, et al. Intratumoral Heterogeneity Analysis Reveals Hidden Associations between Protein Expression Losses and Patient Survival in Clear Cell Renal Cell Carcinoma. Oncotarget. 2017. PMID: 28445125.
  28. Joshi SS, Uzzo RG. Renal Tumor Anatomic Complexity: Clinical Implications for Urologists. The Urologic Clinics of North America. 2017;44(2):179-187. PMID: 28411910.
  29. Jung S, Allen N, Arslan AA, et al. Demographic, Lifestyle, and Other Factors in Relation to Antimullerian Hormone Levels in Mostly Late Premenopausal Women. Fertility and Sterility. 2017;107(4):1012-1022.e1012. PMID: 28366409.
  30. Klein-Szanto AJ, Bassi DE. Proprotein Convertase Inhibition: Paralyzing the Cell’s Master Switches. Biochemical Pharmacology. 2017. PMID: 28456517.
  31. Kumar SK, Callander NS, Alsina M, et al. Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JNCCN. 2017;15(2):230-+. PMID: 28188192
  32. Kutikov A, Smaldone MC. The Small Renal Mass and Its Management in Urologic Practice. The Urologic Clinics of North America. 2017;44(2):xvii. PMID: 28411925.
  33. Lawler AC, Ghiraldi EM, Tong C, Friedlander JI. Extracorporeal Shock Wave Therapy: Current Perspectives and Future Directions. Current Urology Reports. 2017;18(4). PMID: 28247327
  34. Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of Serum Histidine and Plasma Tryptophan as a Potential Biomarker to Detect Clear Cell Renal Cell Carcinoma. Journal of Translational Medicine. 2017;15(1):72. PMID: 28385150. PMC5383954.
  35. Li PD, Hu JL, Ma C, et al. Upregulation of the Long Non-Coding Rna Pvt1 Promotes Esophageal Squamous Cell Carcinoma Progression by Acting as a Molecular Sponge of Mir-203 and Lasp1. Oncotarget. 2017. PMID: 28404954.
  36. Liederbach E, Kyrillos A, Wang CH, Liu JC, Sturgis EM, Bhayani MK. The National Landscape of Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. International Journal of Cancer. 2017;140(3):504-512. PMID: 27667729.
  37. Longacre ML, Valdmanis VG, Handorf EA, Fang CY. Work Impact and Emotional Stress among Informal Caregivers for Older Adults. The Journals of Gerontology Series B, Psychological Sciences and Social Sciences. 2017;72(3):522-531. PMID: 27048567.
  38. Lupey-Green LN, Moquin SA, Martin KA, et al. Parp1 Restricts Epstein Barr Virus Lytic Reactivation by Binding the Bzlf1 Promoter. Virology. 2017;507:220-230. PMID: 28456021.
  39. Lynch SM, Mitra N, Ravichandran K, et al. Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiology, Biomarkers & Prevention. 2017;26(4):553-560. PMID: 28373169.
  40. Meng Y, Cai KQ, Moore R, et al. Pten Facilitates Epiblast Epithelial Polarization and Proamniotic Lumen Formation in Early Mouse Embryos. Developmental Dynamics. 2017. PMID: 28387983.
  41. Miller MP, Kostakoglu L, Pryma D, et al. Reader Training for the Re-Staging of Biochemically Recurrent Prostate Cancer Using Fluciclovine (18f) Pet/Ct. Journal of Nuclear Medicine. 2017. PMID: 28385791.
  42. Moore KN, Borghaei H, O’Malley DM, et al. Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (Imgn853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Solid Tumors. Cancer. 2017. PMID: 28440955.
  43. Moore KN, Martin LP, O’Malley DM, et al. Safety and Activity of Mirvetuximab Soravtansine (Imgn853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of Clinical Oncology. 2017; 35(10):1112-1118. PMID: 28029313
  44. Mortazavi SMJ, Zarei S, Taheri M, et al. Sensitivity to Antibiotics of Bacteria Exposed to Gamma Radiation Emitted from Hot Soils of the High Background Radiation Areas of Ramsar, Northern Iran. The International Journal of Occupational and Environmental Medicine. 2017;8(2):80-84. PMID: 28432369.
  45. Necchi A, Pond GR, Smaldone MC, et al. Robot-Assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-Invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study. European Urology Focus. 2017.
  46. Nizovtseva EV, Clauvelin N, Todolli S, et al. Nucleosome-Free DNA Regions Differentially Affect Distant Communication in Chromatin. Nucleic Acids Research. 2017;45(6):3059-3067. PMID: 27940560. PMCID: PMC5389534
  47. Obeid EI, Hall MJ, Daly MB. Multigene Panel Testing and Breast Cancer Risk: Is It Time to Scale Down? JAMA Oncology. 2017. PMID: 28418452.
  48. Pazina T, Shemesh A, Brusilovsky M, Porgador A, Campbell KS. Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression. Frontiers in Immunology. 2017;8:369. PMID: 28424697. PMC5371597.
  49. Ragin C, Liu JC, Jones G, et al. Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients. Carcinogenesis. 2017;38(2):218-229.
  50. Ralff MD, Kline CLB, Kucukkase OC, et al. Onc201 Demonstrates Anti-Tumor Effects in Both Triple Negative and Non-Triple Negative Breast Cancers through Trail-Dependent and Trail-Independent Mechanisms. Molecular cancer therapeutics. 2017. PMID: 28424227.
  51. Reese JB, Beach MC, Smith KC, et al. Effective Patient-Provider Communication About Sexual Concerns in Breast Cancer: A Qualitative Study. Supportive Care in Cancer. 2017. PMID: 28451911.
  52. Ristau BT, Correa AF, Uzzo RG, Smaldone MC. Active Surveillance for the Small Renal Mass: Growth Kinetics and Oncologic Outcomes. The Urologic clinics of North America. 2017;44(2):213-222. PMID: 28411913.
  53. Ristau BT, Kutikov A, Uzzo RG, Smaldone MC. Active Surveillance for Small Renal Masses: When Less Is More. European Urology Focus. 2017.
  54. Roche LM, Niu X, Stroup AM, Henry KA. Disparities in Female Breast Cancer Stage at Diagnosis in New Jersey: A Spatial-Temporal Analysis. JPHMP. 2016. PMID: 28430705.
  55. Saribas AS, Coric P, Hamazaspyan A, et al. Emerging from the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses. Journal of Cellular Physiology. 2016;231(10):2115-2127. PMID: 26831433. PMC5217748.
  56. Segal S, John G, Sammel M, et al. Urinary Incontinence and Other Pelvic Floor Disorders after Radiation Therapy in Endometrial Cancer Survivors. Maturitas. 2017. PMID: 28396018.
  57. Smaldone MC, Egleston B, Hollingsworth JM, et al. Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. Medical Care. 2017;55(4):398-404. PMID: 27820596. PMCID: PMC5352513.
  58. Soni RS, Ebersole B, Jamal N. Does Even Low-Grade Dysphonia Warrant Voice Center Referral? Journal of Voice. 2017. PMID: 28396220.
  59. Tong C, Daskalakis N, Edwards DC, Cahn DB, Belkoff L, Geynisman DM. Malignant Infiltration of the Penis from Urothelial Carcinoma of the Bladder. Urology. 2017. PMID: 28373110.
  60. Waldorf B, Lee Z, Kidd L, et al. Robotic Buccal Ureteroplasty: A Review of the Current Literature. Current Urology Reports. 2017;18(5):40. PMID: 28401476.
  61. Wei S, Layfield LJ, LiVolsi VA, Montone KT, Baloch ZW. Reporting of Fine Needle Aspiration (Fna) Specimens of Salivary Gland Lesions: A Comprehensive Review. Diagnostic Cytopathology. 2017. PMID: 28371507.
  62. Weidhaas JB, Harris J, Schaue D, et al. The Kras-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology. 2017;3(4):483-491. PMID: 28006059.
  63. Weinberg DS, Lin JE, Foster NR, et al. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prevention Research (Philadelphia, PA). 2017. PMID: 28396341.
  64. Weng YL, An R, Cassin J, et al. An Intrinsic Epigenetic Barrier for Functional Axon Regeneration. Neuron. 2017;94(2):337-346.e336. PMID: 28426967.
  65. Whelan KA, Chandramouleeswaran PM, Tanaka K, et al. Autophagy Supports Generation of Cells with High Cd44 Expression Via Modulation of Oxidative Stress and Parkin-Mediated Mitochondrial Clearance. Oncogene. 2017. PMID: 28414310.
  66. Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN Guidelines® Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured Updates to the NCCN Guidelines. JNCCN. 2017;15(3):293-311. PMID: 28275031
  67. Xi H, Zhang Y, Xu Y, et al. Caspase-1 Inflammasome Activation Mediates Homocysteine-Induced Pyrop-Apoptosis in Endothelial Cells. Circulation research. 2016;118(10):1525-1539. PMID: 27006445. PMC4867131.
  68. Xu Q, Tang Q, Katsonis P, et al. Benchmarking Predictions of Allostery in Liver Pyruvate Kinase in Cagi4. Human Mutation. 2017. PMID: 28370845.
  69. Xue J, McKay JD, Grimm J, et al. Small-Field Dose Measurements Using Plastic Scintillation Detector in Heterogeneous Media. Medical physics. 2017. PMID: 28398596.
  70. Yoo SK, Ahmed AA, Ileto J, et al. Industry Funding among Leadership in Medical Oncology and Radiation Oncology in 2015. International Journal of Radiation Oncology, Biology, Physics. 2017. PMID: 28366578.
  71. Younes A, Hilden P, Coiffier B, et al. International Working Group Consensus Response Evaluation Criteria in Lymphoma (Recil 2017). Annals of Oncology. 2017. PMID: 28379322.
  72. Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of Death among Cancer Patients. Annals of Oncology. 2017;28(2):400-407.

Two things of note. If your research was funded, in full or in part, by the Core Grant you must acknowledge the Core Grant in your paper. For examples of how to acknoweldge grant funding from the NIH, NSF, HHS, and other grantors see the Acknowledging Grant Funding tab of our NIH Public Access Compliance guide. Finally, unless the publisher deposits articles with the NIHMS (NIH Manuscript Submission System) for inclusion in PubMed Central, the primary author (or designated delegate) is responsible for depositing the final approved manuscript and all tables and images with the NIHMS. Do not deposit the publisher’s PDF with the NIHMS, as that is the publisher’s property. Elsevier, Wiley, JAMA, BMJ may deposit their PDFs as they see fit, you the author, however, may not. For instructions on how to deposit a manuscript with the NIHMS, see the NIH Public Access Compliance guide.


EndNote’s NIH Output Style Helps You with the new NIH Bibliography Format

We have been getting phone calls of late regarding changes to the NIH bibliography format. As of March 2016, “anyone submitting an application, proposal or report to the NIH must include the PMC reference number (PMCID) when citing applicable papers that they author or that arise from their NIH-funded research.” The other requirement is that all authors of a given article be listed in the bibliographic citation. If you have EndNote, you can kill both birds with one stone.

Back in 2014, the NIH created an EndNote output style called NIH (Grant Format). In this style, all of the authors are included and the PMID and PMCID are added automatically. To see if the NIH format is included in your version of EndNote:

  1. In EndNote for Windows, click on the Bibliographic Output Style drop-down arrow located in the EndNote toolbar.
  2. Check the list provided and click NIH, if it appears.

The drop-down list of output styles is an alphabetical list of your most heavily-used styles. If you do not see NIH on that list, proceed as follows:

  1. In EndNote for Windows, click on the Bibliographic Output Style drop-down arrow located in the EndNote toolbar.
  2. Click Select Another Style.
  3. Output styles are arranged alphabetically by name. Scroll down to and click NIH if it appears on the list.
  4. Click Choose.

If you do not see NIH in the Choose a Style box, it may be installed just not visible:

  1. In EndNote for Windows, click Edit, then click Output Styles, and then click Open Style Manager.
  2. In the EndNote Styles box, scroll down to and select the NIH checkbox.
  3. Close the EndNote Styles box.

If you do not see NIH in the EndNote Styles box, it may not be installed and proceed as follows:

  1. Google EndNote downloads.
  2. Click Downloads | EndNote | Clarivate Analytics
  3. Scroll down to and click Add output styles.
  4. In the text box located directly under the Publisher drop-down list, type NIH.
  5. Click NIH (Grant Format).
  6. Click Download this Style.
  7. In the Opening NIH.ens box, make sure that Open with is selected and EndNote X8 (or X7) appears as the default.
    If you do not see EndNote, click the down arrow then click Other, click EndNote, and then click OK.
  8. Click OK.
  9. In EndNote, click File and then click Save As.
  10. In the Style Name text box, delete Copy if it appears.
  11. Click Save.

If your article has been submitted to PMC by the publisher and does not have a PMCID yet use “PMC Journal – In Process”. If either the publisher, the author, or the author’s designee has submitted the manuscript using the NIHMS, provide a valid NIH Manuscript Submission System reference number (NIHMSID) until the PMCID becomes available. Whatever method of deposit you use, be sure to add the PMCID when it becomes available. If your article was accepted for publication before the NIH Public Access Policy went into effect, then no special notation is required.

For more information about when to include the PMCID see, NIH Public Access Policy Include PMCID in Citation.